Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
Pharmaceuticals, Inc. (Pink Sheets: RHGP) (“Renhuang” or the “Company”), a
developer, manufacturer and distributor of botanical products,
bio-pharmaceuticals and traditional Chinese medicines (“TCM”), today announced
that the State Intellectual Property Office of
(“SIPO”) successfully completed a preliminary review of the Company’s patent
application for its advanced proprietary Schisandra Lignin Extraction Method.
medicinal and health benefits, has a protective effect on the liver and is
effective as a sedative for treating insomnia and central nervous system
depression. Lignin compounds have been shown as a good source of powerful
anti-oxidants with promising benefits in fighting major conditions, including
HIV, cancer and high blood pressure. Renhuang’s proprietary Schisandra lignin
extraction method enables the Company to obtain higher purity of lignin from
the plant, which may substantially enhance the efficacy of medicines produced
from these compounds. The Company’s patent application has now entered the
SIPO comprehensive examination phase, which is typically a two year process.
If approved by the SIPO, the patent will provide Renhuang market exclusivity
for its Schisandra-based products for a period of 16 to 18 years.
“We are pleased that our advanced proprietary Schisandra Lignin Extraction
Method patent application has passed an important stage in the patent approval
process,” said Mr.
Inc. “We continue to strive towards securing patents on our unique proprietary
extraction methods, which is an important part of our long-term growth
strategy. The successful development of our high-quality, proprietary
extraction method provides a strong foundation for advancing the development
of Schisandra based products and is expected to strengthen our competitive
edge during the commercialization of the product in the future.”
About Renhuang Pharmaceuticals, Inc.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development,
manufacturing, and distribution of botanical products, bio-pharmaceutical
products, and traditional Chinese medicines (“TCM”), in
GMP-certified production facilities in Ah City, Dongfanghong and Qingyang.
The Company distributes its botanical anti-depression and nerve-regulation
products, biopharmaceutical products, and botanical antibiotic and OTC TCMs
through its network of over 3,000 distributors and over 70 sales centers
across 24 provinces in
Safe Harbor Statement
This press release contains certain statements that may include
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are based upon management’s
beliefs, assumptions and expectations of the Company’s future operations and
economic performance, taking into account the information currently available
to management. These statements are not statements of historical fact.
Forward-looking statements involve risks and uncertainties, some of which are
not currently known that may cause actual results, performance or financial
condition to be materially different from the expectations of future results,
performance or financial condition expressed or implied in any forward-looking
statements. These forward-looking statements are based on current plans and
expectations and are subject to a number of uncertainties including, but not
limited to, the Company’s ability to secure and enforce patent rights for its
proprietary extraction methods, successfully develop and commercialization of
its Schisandra-based drugs, ability to manage expansion of its operations
effectively, and other factors detailed in the Company’s annual report on Form
10-K and other filings with the Securities and Exchange Commission. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information presented herein.
For more information, please contact: Company Contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Tel: +86-451-5392-5461 Email: firstname.lastname@example.org CCG Investor Relations: Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: email@example.com Ms. Lei Huang, Account Manager Phone: +1-646-833-3417 (New York) Email: firstname.lastname@example.org Web: http://www.ccgirasia.com
SOURCE Renhuang Pharmaceuticals, Inc.